VRTX - Vertex Pharmaceuticals Inc

VRTX - Vertex Pharmaceuticals Inc

https://www.vrtx.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals

Motley Fool • 4 hours, 19 minutes ago • score: 0.07

Here's why you can't find a Wall Street analyst who will tell you to sell this stock.

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years - Vertex Pharmaceuticals ( NASDAQ:VRTX )

Benzinga • 3 days, 23 hours ago • score: 0.39

Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 4.73% on an annualized basis producing an average annual return of 17.22%. Currently, Vertex Pharmaceuticals has a market capitalization of $100.71 billion.

Vertex Pharmaceuticals ( VRTX ) Stock Slides as Market Rises: Facts to Know Before You Trade

Zacks Commentary • 4 days, 17 hours ago • score: 0.22

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $388.55, marking a -2% move from the previous day.

Why This Biotech Company Could Be a Growth Stock Powerhouse

Motley Fool • 1 week, 4 days ago • score: 0.25

Recent developments aren't as devastating to the company's prospects as some might think.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

52W High

$519.88

52W Low

$362.50

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.44

Valuation

Fair

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

28.17

Forward P/E (<15 better)

20.28

EV/EBITDA (<8 favorable)

21.07

EV/Revenue (<3 favorable)

8.47

P/S (TTM) (<3 favorable)

8.89

P/B (<3 favorable)

5.91

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.14%

Institutions (25–75% balanced)

98.19%

Shares Outstanding

256,391,000

Float

255,578,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

11,418,800,000

Gross Profit (TTM)

6,383,800,000

EPS (TTM)

14.06

Profit Margin (>10% good)

0.32%

Operating Margin (TTM) (higher better)

0.39%

ROE (TTM) (>15% strong)

0.23%

EPS YoY (Quarterly) (>10% good)

-0.41

Revenue YoY (Quarterly) (>8% good)

0.12

Momentum

Bearish momentum

Value

-6.3227

Previous

-6.8095

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025